US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

GSK plc ADRhedged

69.86

-0.6698-0.95%

Volume:112

Turnover:8K

Market Cap:698.64K

PE:- -

High:70.28

Open:70.28

Low:69.86

Close:70.53

52wk High:85.03

52wk Low:55.03

Shares:10.00K

Float Shares:10.00K

Volume Ratio:0.24

T/O Rate:1.12%

Dividend:2.07

Dividend Rate:2.97%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Xinjiang Bai Hua Clarifies No Role in Innovative Drug Development

AI Reshapes Drug Discovery Foundation, Domestic Industry Chain Expected to Benefit

Global Drugmakers Invest Billions to Boost US Presence

GSK’s NEBULA-1 MASH Cirrhosis Trial: A New Catalyst in Metabolic Liver Disease

GSK's New Drug Launches Will be Key to 2027 Outlook

GlaxoSmithKline (GSK) Receives a Sell from Barclays

GSK Advances New Toddler Pneumococcal Booster, Signaling Ongoing Vaccine Pipeline Momentum

GSK Supply Chain President Registers Sale of Ordinary Shares

GSK's ViiV Healthcare Highlights New Long-Acting Injectable Data on Cabenuva in HIV Treatment

MT Newswires Live

Cabenuva demonstrates superiority to daily oral therapy in adolescents with HIV

GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals

Benzinga Earnings

GSK Licensor's Late-Stage China Study for Risvutatug Rezetecan in Bone Cancer Meets Primary Endpoint

MT Newswires Live

GSK Heading in Right Direction, but Investors Might Stay on Sidelines

GSK Launches Cost-Saving Plan to Accelerate Drug Pipeline

GSK to Build New Global Research Center in Cambridge

MT Newswires Live

Sector Update: Healthcare Stocks Flat to Higher Pre-Bell Tuesday

MT Newswires Live

GSK's R&D Plan Looks Smart

GSK's Savings Plan Can Offset Profitability Hit from HIV Patent Expiration

GSK sees 70p per share dividend for FY26

GSK initiates ‘Accelerate Growth’ program

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/GSKH/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GSKH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","market":"US","secType":"STK","nameCN":"GSK plc ADRhedged","latestPrice":69.8569,"timestamp":1788206400000,"preClose":70.5267,"halted":0,"volume":112,"delay":0,"changeRate":-0.009497112441103996,"floatShares":10001,"shares":10001,"eps":0,"marketStatus":"Pre-Mkt","change":-0.6698,"latestTime":"09-01 08:11:22 EDT","open":70.28,"high":70.28,"low":69.8569,"amount":7863,"amplitude":0.005999,"askPrice":111.77,"askSize":200,"bidPrice":27.95,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788269400000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":69.8569,"nav":70.443211,"aum":704502.553211,"dividendRate":0.029701,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":70.28,"preClose":69.8569,"latestTime":"16:10 EDT","volume":6,"amount":419.1414,"timestamp":1788207004353,"change":0.4231,"changeRate":0.006057,"amplitude":0},"volumeRatio":0.24432801778097152,"impliedVol":0.1633,"impliedVolPercentile":0.3143},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","floatShares":10001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.24432801778097152,"shares":10001,"dividePrice":2.0748,"high":70.28,"amplitude":0.005999,"preClose":70.5267,"low":69.8569,"week52Low":55.03,"pbRate":"--","week52High":85.03,"institutionHeld":0,"latestPrice":69.8569,"eps":0,"divideRate":0.029701,"volume":112,"delay":0,"ttmEps":0,"open":70.28,"prevYearClose":68.2031,"prevWeekClose":70.5267,"prevMonthClose":69.8569,"prevQuarterClose":73.8574,"fiveDayClose":71.5619,"twentyDayClose":71.3803,"sixtyDayClose":72.2308},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GSKH\",params:#limit:5,,,undefined,":[{"date":"2026-06-16","symbol":"GSKH","amount":0.92785,"announcedDate":"2026-06-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-16","defaultRemindTime":1781616600000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-23","payableDate":"2026-06-16","currency":"USD","dateTimestamp":1781582400000,"payDate":"2026-06-23"},{"date":"2026-03-16","symbol":"GSKH","amount":0.36332,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"GSKH","amount":0.78682,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GSKH\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.78682,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.36332,"currency":"USD"},{"executeDate":"2026-06-16","recordDate":"2026-06-16","paymentDate":"2026-06-23","value":0.92785,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GSKH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GSKH\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1174341976","title":"Xinjiang Bai Hua Clarifies No Role in Innovative Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1174341976","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174341976?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:08","pubTimestamp":1786450094,"startTime":"0","endTime":"0","summary":"Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd. (600721.SH) has issued a stock trading risk warning announcement, stating that it is a CRO enterprise primarily focused on the research and development of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBIO","BBP","IBB","BK0216","GDOC","GSKH","PBE","APXH","BIOY","BK0102","600721","WRND","BK4585","XLVI","LFSC","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118729610","title":"AI Reshapes Drug Discovery Foundation, Domestic Industry Chain Expected to Benefit","url":"https://stock-news.laohu8.com/highlight/detail?id=1118729610","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118729610?lang=en_us&edition=fundamental","pubTime":"2026-08-11 14:12","pubTimestamp":1786428745,"startTime":"0","endTime":"0","summary":"A research report from Orient Securities Company Limited highlights that as global regulatory shifts accelerate, the large-scale application of AI in pharmaceuticals is rapidly advancing. It has...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ARTY","03958","SBIO","AGIX","IBB","BBP","BIOY","GSKH","GDOC","BK1564","600958","AIPO","BK0012","BK1147","QTOC","PBE","BK0276","BK0183","WRND","BK0188","APXH","XLVI","LFSC","CHAT","VTHR","BK0028","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658931607","title":"Global Drugmakers Invest Billions to Boost US Presence","url":"https://stock-news.laohu8.com/highlight/detail?id=2658931607","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658931607?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:16","pubTimestamp":1786367800,"startTime":"0","endTime":"0","summary":"FACTBOX-Global drugmakers invest billions to boost US presenceAug 10 (Reuters)-Global drugmakers are expanding their U.S. footprint, pledging billions of dollars to ramp up manufacturing capacity and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL4N4470VR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014559.SGD","LU0265550946.USD","LU0472753341.HKD","IE000MB6IJN5.SGD","LU0545039389.USD","LU1201861249.SGD","LU1829250122.USD","LU0689626769.HKD","LU1032466523.USD","IE00B7KXQ091.USD","BK4532","LU1941712264.USD","LU0321505439.SGD","LU0225283273.USD","LU0965509283.SGD","LU0109394709.USD","LU0203347892.USD","LU1720051108.HKD","LU0795875086.SGD","LU2462157665.USD","BK4578","LU1934455863.HKD","LLYX","SG9999015978.USD","LU1674673428.USD","IE0000B7K699.USD","LU0114720955.EUR","LU0426417589.USD","LU0237698245.USD","LU0211327993.USD","LU1974910355.USD","LU2237443895.HKD","LU2461242641.AUD","LU0820561909.HKD","LU1291159041.SGD","LU1623119135.USD","LU0889566641.SGD","IBBQ","LU2129689431.USD","LU0306807586.USD","LU2211815571.USD","LU2552382215.SGD","LU2112291526.USD","LU1323610961.USD","IE00B1XK9C88.USD","BK7067","BK7511","LU2471134523.USD","BK4550","TMED","HRTS","IE00BSNM7G36.USD","LU1989772840.SGD","LU0672654240.SGD","LU2023251221.USD","LU1935042991.SGD","LU0868494617.USD","PAWZ","TBXU","LU0353189763.USD","LU1670711040.USD","LU1894683264.USD","GSKH","SGXZ31699556.SGD","SG9999018857.SGD","IE00B3T34201.USD","BK4592","LU2430703095.HKD","LU0385154629.USD","LU2471134952.CNY","IE00B2B36J28.USD","LU2023250843.SGD","LU0708995401.HKD","JNJ","LU1366192091.USD","LU2491050154.USD","LU0210536198.USD","LU2487616109.SGD","LU1145028129.USD","IE00B894F039.SGD","LU2596442595.SGD","LU1280957306.USD","LU1929549753.HKD","IE00BN8TJ469.HKD","LU2896262040.SGD","IE000M9KFDE8.USD","LU2357305700.SGD","LU0985320562.USD","SG9999015945.SGD","SG9999014906.USD","LU1066051811.HKD","LU1989771016.USD","LU2265009873.SGD","LU0942090050.USD","LU0648001328.SGD","LU2430703178.SGD","LU2361044865.SGD","GB00BDT5M118.USD","AMGN","LU2129689514.USD","SG9999013999.USD","LU1674673691.USD","LU0354030511.USD","LU0823434740.USD","LU0965509010.AUD","LU1066051225.USD","LU1670710661.SGD","MEDI","SG9999014898.SGD","TRUH","IE00BFSS7M15.SGD","LU1035775433.USD","IE00BKDWB100.SGD","LU1699723380.USD","LU1914381329.SGD","LU1221951129.SGD","LU1868836914.USD","LU0130102774.USD","IE00BJJMRX11.SGD","IE00BK4W5L77.USD","LU0787776722.HKD","LU0795875169.SGD","LU2462591350.SGD","LU2756315318.SGD","AGNG","LU2403377893.USD","LU0124676726.USD","SG9999014575.USD","RXL","SGXZ81514606.USD","LU2106854487.HKD","IE0001KFT4U8.USD","LU1221951046.USD","LU2750360997.AUD","LU0792757196.USD","LU0708994859.HKD","LU2360106947.USD","LU0106261372.USD","LU2491049909.HKD","LLII","JDOC","LU0267386448.USD","IE00BKVL7J92.USD","LU1267930573.SGD","LU2028103732.USD","BK4588","LU1064131342.USD","GSK","LU0823416689.USD","LU1496350502.SGD","PJP","LU0683600562.USD","LU0069063385.USD","LU0738911758.USD","LU0456855351.SGD","BK4516","GLAM","LU0823434583.USD","THNR","LU1232071149.USD","LU1979441026.SGD","LU2129689605.HKD","LU1162221912.USD","LU1629891620.HKD","LU2417539215.USD","SG9999001176.USD","IE0002141913.USD","LU0320765059.SGD","LU0964807845.USD","LU1732800096.USD","LU1244550221.USD","LU2357627491.SGD","SG9999014542.SGD","LU0210528500.USD","LU1804176565.USD","LU0198837287.USD","LU1923622614.USD","LU0861579265.USD","LU1814569148.SGD","LU1551013342.USD","IE0004445015.USD","LU1894683348.USD","CANC","LU1037948541.HKD","LU0170899867.USD","LU1934455277.USD","VHT","LU2213496289.HKD","LU2237443622.USD","IE00B19Z9P08.USD","IE00BVYPNV92.GBP","LU0882574055.USD","SG9999011175.SGD","BK4585","IE00B1BXHZ80.USD","LU0345769128.USD","LU2089283258.USD","IE00BWXC8680.SGD","IE00BJT1NW94.SGD","SG9999001440.SGD","ABBV","LU2237443382.USD","LU2505996681.GBP","SG9999001176.SGD","IE000WAW04H5.SGD","LU0006306889.USD","LU2505996509.AUD","LU1121112475.USD","IE00BGHQF631.EUR","LU0511384066.AUD","LU1883839398.USD","LU0158827781.USD","IE0005OL40V9.USD","LU2491050071.SGD","IE00B42XCP33.USD","LU1868837300.USD","LU0353189680.USD","IE000SO60NU8.SGD","SG9999002232.USD","LU2242646821.SGD","LU0203345920.USD","LU1043141396.HKD","LU2125909247.SGD","LU2023250330.USD","SG9999018865.SGD","LU2087621335.USD","IE00BVYPNW00.USD","SG9999014880.SGD","LU1868836757.USD","IE00BKPKM429.USD","BK4534","LU0432979614.USD","IE00B19Z9Z06.USD","LU2347655156.SGD","LU2756315664.SGD","LU0158827948.USD","LU2063271972.USD","LU1720051017.SGD","LU2552382058.USD","SG9999015341.SGD","LU0889565916.HKD","FHLC","LU2125909593.SGD","ELIL","LU2168564065.EUR","FTXH","BIB","PPH","LU1917777945.USD","LU0234570918.USD","LU0057025933.USD","LU1506573853.SGD","IYH","LU1732799900.SGD","LU0203201768.USD","IE0004445239.USD","LU2361044949.HKD","LU2168563687.JPY","IE00BJJMRY28.SGD","LU0265550359.USD","LU0786609619.USD","LU0053666078.USD","LU1551013425.SGD","LU0545562505.USD","LU1069347547.HKD","LU2168564149.EUR","LU0122379950.USD","IE000F7OJYX1.SGD","PBE","LU2237438978.USD","LU2750360641.GBP","LU2471134879.HKD","LU1093756325.SGD","LU1868837136.USD","LU2746668461.USD","LU2471134796.USD","LU2552382132.HKD","LU2237443549.SGD","IE00B4R5TH58.HKD","CSL.AU","LU1061106388.HKD","LU0162691827.USD","LU1196500208.SGD","BK4566","LU0094547139.USD","IE00BZ1G4Q59.USD","LU1718418525.SGD","LU0323591593.USD","ELIS","LU2236285917.USD","BK4533","BMY","LU2089284900.SGD","IE00B3PB1722.GBP","LU0980610538.SGD","LU2433249047.HKD","LU1116320737.USD","LU1069344957.HKD","LU0912757837.SGD","IE00BDGV0183.EUR","LU2168564495.EUR","SG9999014914.USD","MHIP","LU2271345857.HKD","LU1983299246.USD","LU0211331839.USD","SGXZ51526630.SGD","LU2087625088.SGD","LLYZ","LU2237443465.HKD","LU2361045086.USD","IE00B7SZLL34.SGD","PFE","LU0868494708.USD","IBB","LU1244550577.SGD","MEDX","LU0553294199.USD","LU2237443978.SGD","LU0058720904.USD","LU1003077747.HKD","LU2456880835.USD","LU0943347566.SGD","LU1228905037.USD","LU0097036916.USD","LU0256863902.USD","IE00B775H168.HKD","LU2023250504.SGD","LU1059921491.USD","LU2089984988.USD","LU0426412945.USD","BMED","LU2468319806.SGD","LU0471298694.HKD","IE00BFTCPJ56.SGD","LU1023059063.AUD","LU1988902786.USD","SG9999003800.SGD","SG9999002224.SGD","LU1267930490.SGD","LU0225771236.USD","BK4504","LU0345769631.USD","IE00BLSP4452.SGD","IE00BJLML261.HKD","LU2168564222.USD","LU2360032135.SGD","LU1228905540.USD","LU2133065610.SGD","CURE","LU0266013472.USD","IXJ","LLY","LU0726765562.USD","LU1127390331.HKD","BK4599","LU0640476718.USD","IE00BFSS8Q28.SGD","SG9999017495.SGD","BK4139","IE0009355771.USD","IE00B4JS1V06.HKD","BK4581","MRK","LU1066051498.USD","LU0096364046.USD","LU1571399168.USD","SGXZ57979304.SGD","IE000BZT7R73.USD","BK4007","IE00BK4W5M84.HKD","LU1868836591.USD","SGXZ99366536.SGD","LU0238689110.USD","IHE","LU1074936037.SGD","LU0310800379.SGD","LU0070217475.USD","GSK.UK","LU0211328371.USD","LU0320765646.SGD","LU0477156953.USD","LU1267930813.SGD","LU0310799852.SGD","IE00B19Z3581.USD","LU0820561818.USD","LU0203202063.USD","IE0034235303.USD","SG9999015358.SGD","WDNA","LU0174119429.USD","SGXZ80539844.SGD","LU0471298777.SGD","XLV","LU1548497426.USD","LU1261432733.SGD","LU0070302665.USD","LU0321505868.SGD","BK7508","LU2108987350.USD","LU0109391861.USD","LU1934455194.USD","LU0098860793.USD","LU0965509101.SGD","IE00B19Z3B42.SGD","LU1585245621.USD","SG9999014567.USD","LU0320765489.SGD","LU2430703251.USD","LU0985481810.HKD","LU1496350171.SGD","LU1093756168.USD","IE0002270589.USD","LU0661504455.SGD","AZNH","LU0208291251.USD","GDOC","LU0061475181.USD","GILD","BK4568","LU0256863811.USD","LU1670711123.USD","LU0965508806.USD","LU0289739699.SGD","BK4583","04332","LU0316494557.USD","LU1712237335.SGD","LU0395794307.EUR","LU2746668974.SGD","LU0820562030.AUD","LU2111349929.HKD","ILDR","LU2602419157.SGD","LU0949170772.SGD","BIIB","LU0225284248.USD","LU2125154778.USD","BBH","AZN","LU1670628061.USD","IE00BJJMRZ35.SGD","SG9999015986.USD","LU0133085943.USD","LU1057294990.SGD","LU1035773651.USD","LU2242652126.USD","LU2592432038.USD","LU0128525929.USD","LU0345770993.USD","BK7501","LU1670627923.USD","LU0859254822.USD","LU1670710588.SGD","LU1066053197.SGD","IE00BLSP4239.USD","LU0029864427.USD","LU0882574139.USD","LU0354030438.USD","LU2347655073.USD","LU0289961442.SGD","LU0289739343.SGD","LU0072461881.USD","LU1430594728.SGD","BK4559","LU0130517989.USD","LU0689472784.USD","LU2264538146.SGD","IE00BBT3K403.USD","LU0345770308.USD","LU0466842654.USD","LU2125154935.USD","LU0306806265.USD","IE00BN29S564.USD","SG9999015952.SGD","LU1244550494.USD","LU1116320901.HKD","IE00BFXG1179.USD","LU1032955483.USD","LU0994945656.USD","LU2324357040.USD","LU1037948897.HKD","LU1043141123.HKD","OZEM","LU1839511570.USD","LU1267930730.SGD","LU1941712348.USD","LU1989772923.USD","LU0417517546.SGD","LU1778281490.HKD","LU0234572021.USD","LU0320765992.SGD","LU0079474960.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657529622","title":"GSK’s NEBULA-1 MASH Cirrhosis Trial: A New Catalyst in Metabolic Liver Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2657529622","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657529622?lang=en_us&edition=fundamental","pubTime":"2026-08-06 00:31","pubTimestamp":1785947469,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. The NEBULA-1 phase 3 study from GlaxoSmithKline aims to test efimosferm...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsks-nebula-1-mash-cirrhosis-trial-a-new-catalyst-in-metabolic-liver-disease?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsks-nebula-1-mash-cirrhosis-trial-a-new-catalyst-in-metabolic-liver-disease?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSKH","LU1829250122.USD","GSK.UK","BK4532","BK4007","BK4588","BK4585","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656552722","title":"GSK's New Drug Launches Will be Key to 2027 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2656552722","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656552722?lang=en_us&edition=fundamental","pubTime":"2026-08-04 22:38","pubTimestamp":1785854280,"startTime":"0","endTime":"0","summary":"1438 GMT - GSK's newly launched drugs will be key to reduce risk on the U.K. pharmaceutical company's outlook for next year, analysts at J.P. Morgan say. GSK recently launched blood-cancer drug Blenrep and asthma treatment Exdensur, while lung-cancer medicine Jideytro--which the company bought through its acquisition of Nuvalent--received U.S. approval last month. The trajectory of these products and others that are expected to reach the market next year like hepatitis B drug bepirovirsen and neladalkib--another lung-cancer drug from Nuvalent--will be increasingly focus for investors, the analysts say. The company's efforts to accelerate its strategy look encouraging but, with the next pivotal study results due to come only in 2028, potential risks to earnings in the near term might draw investors' attention, they add. Shares rise 0.2%.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"GSK's New Drug Launches Will be Key to 2027 Outlook","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSKH","BK4007","LU1829250122.USD","BK4532","GSK.UK","BK4588","BK4585","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656535373","title":"GlaxoSmithKline (GSK) Receives a Sell from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2656535373","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656535373?lang=en_us&edition=fundamental","pubTime":"2026-08-04 15:57","pubTimestamp":1785830258,"startTime":"0","endTime":"0","summary":"In a report released today, James Gordon CFA from Barclays maintained a Sell rating on GlaxoSmithKline, with a price target of £19.00. According to...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/glaxosmithkline-gsk-receives-a-sell-from-barclays-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/glaxosmithkline-gsk-receives-a-sell-from-barclays-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK.UK","GSK","BK4007","BK4585","BK4588","BK4532","GSKH","CFA","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655804705","title":"GSK Advances New Toddler Pneumococcal Booster, Signaling Ongoing Vaccine Pipeline Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2655804705","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655804705?lang=en_us&edition=fundamental","pubTime":"2026-07-31 00:32","pubTimestamp":1785429167,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GlaxoSmithKline is running a Phase 1 trial called “A Phase 1, Observer-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-advances-new-toddler-pneumococcal-booster-signaling-ongoing-vaccine-pipeline-momentum?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-advances-new-toddler-pneumococcal-booster-signaling-ongoing-vaccine-pipeline-momentum?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU1829250122.USD","BBC","GSKH","GSK","BK4588","BK4007","BK4532","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655066588","title":"GSK Supply Chain President Registers Sale of Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2655066588","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655066588?lang=en_us&edition=fundamental","pubTime":"2026-07-30 22:32","pubTimestamp":1785421948,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ( ($GB:GSK) ) has provided an update. GSK disclosed that Regis Simard, the company’s President of Global Supply Chain, has sold 38,...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-supply-chain-president-registers-sale-of-ordinary-shares?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-supply-chain-president-registers-sale-of-ordinary-shares?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","BK4585","BK4007","GSK.UK","BK4588","LU1829250122.USD","GSK","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655894955","title":"GSK's ViiV Healthcare Highlights New Long-Acting Injectable Data on Cabenuva in HIV Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2655894955","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655894955?lang=en_us&edition=fundamental","pubTime":"2026-07-29 23:27","pubTimestamp":1785338827,"startTime":"0","endTime":"0","summary":"GSK's  majority-owned ViiV Healthcare unit reported trial data that back Cabenuva's, also known as cabotegravir plus rilpivirine, potential as a long-acting injectable HIV treatment, according to a Wednesday statement.The LATA trial's week 96 results demonstrated Cabenuva's superiority over daily oral therapy in 476 virologically suppressed adolescents of ages 12 to 19 years with HIV in certain African countries, GSK said. Meanwhile, data from the US-based OPERA cohort showed that Cabenuva maintained virologic suppression comparable with daily oral therapy in 6,800 adults with HIV, GSK added.GSK also said six-month follow-up data from the phase 1 CLARITY trial supported a \"more favorable\" injection experience with long-acting cabotegravir, compared with lenacapavir, after a single dose.The company is also investigating an intramuscular formulation of cabotegravir dosed three times a year for HIV prevention, with data to be presented at a future medical event, according to the statement","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GSK.UK","GSK","LABU","XLV","BK4581","BK4007","LU0029874061.USD","BK4585","BK4532","BK4588","GSKH","XBI","BK4137","HCSG","LU1829250122.USD","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655997158","title":"Cabenuva demonstrates superiority to daily oral therapy in adolescents with HIV","url":"https://stock-news.laohu8.com/highlight/detail?id=2655997158","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655997158?lang=en_us&edition=fundamental","pubTime":"2026-07-29 22:25","pubTimestamp":1785335147,"startTime":"0","endTime":"0","summary":"GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK with Shionogi as a shareholder, announced data to...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cabenuva-demonstrates-superiority-to-daily-oral-therapy-in-adolescents-with-hiv-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cabenuva-demonstrates-superiority-to-daily-oral-therapy-in-adolescents-with-hiv-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK","BK4007","XBI","XLV","BK4585","BK4581","GSK.UK","GSKH","LU1829250122.USD","BK4588","BK4532","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655816808","title":"GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals","url":"https://stock-news.laohu8.com/highlight/detail?id=2655816808","media":"Benzinga Earnings","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655816808?lang=en_us&edition=fundamental","pubTime":"2026-07-29 01:30","pubTimestamp":1785259857,"startTime":"0","endTime":"0","summary":"GSK beats Q2 revenue and earnings estimates, launches a $2.52B cost-savings program, and updates its 2026 guidance.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/26/07/60737296/gsk-races-to-protect-profits-before-its-hiv-blockbuster-faces-generic-rivals","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK","BK4007","BK4585","GSK.UK","GSKH","LU1829250122.USD","BK4588","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655888693","title":"GSK Licensor's Late-Stage China Study for Risvutatug Rezetecan in Bone Cancer Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2655888693","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655888693?lang=en_us&edition=fundamental","pubTime":"2026-07-28 23:54","pubTimestamp":1785254093,"startTime":"0","endTime":"0","summary":"GSK  licensor Hansoh's phase 3 trial of risvutatug rezetecan in osteosarcoma, the most common primary bone cancer, achieved its primary endpoint in progression-free survival, GSK said Tuesday.The trial, which was conducted in China in patients with osteosarcoma who have progressed or relapsed after receiving at least two prior lines of systemic therapy, showed that the therapy led to a statistically significant improvement in progression-free survival compared with chemotherapy, according to the statement.Hansoh also reported consistent benefit across secondary endpoints like overall survival, GSK added.Safety profile was consistent with previous findings in the same tumor type, with no new safety signals identified, the company said. Hansoh will use the trial data for regulatory submissions in China, GSK said.Price: 53.96, Change: +1.98, Percent Change: +3.80","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","GSK","GSKH","GSK.UK","BK4007","LU1829250122.USD","BK4532","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654886478","title":"GSK Heading in Right Direction, but Investors Might Stay on Sidelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2654886478","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654886478?lang=en_us&edition=fundamental","pubTime":"2026-07-28 22:10","pubTimestamp":1785247800,"startTime":"0","endTime":"0","summary":"1410 GMT - GSK's research-and-development plan seems a step in the right direction, but investors might stay on the sidelines until the U.K. drugmaker is closer to its destination, Citi analysts say in a research note. The company unveiled plans to target annual cost savings of 1.9 billion pounds by 2029 to fund its drug pipeline and aid profitability. The plan involves a new R&D center in Cambridge, England, and a faster development path for seven drugs across 18 indications, doubling the number of late-stage studies due to start this year, Citi says. \"Overall the ambition is heading in the right direction but we think the market will wait for delivery,\" the analysts say. Shares jump 6%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1829250122.USD","BK4211","ISBC","GSKH","GSK","BK4588","BK4007","BK4532","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654000299","title":"GSK Launches Cost-Saving Plan to Accelerate Drug Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2654000299","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654000299?lang=en_us&edition=fundamental","pubTime":"2026-07-28 21:55","pubTimestamp":1785246900,"startTime":"0","endTime":"0","summary":"GSK said it is launching a three-year program to cut costs and reinvest in its drug pipeline, seeking to protect profitability from the patent expiration of a key HIV drug later this decade.The U.K. d","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1829250122.USD","BK4585","BK4532","AAQC","BK4007","GSK","BK4588","GSKH","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654007170","title":"GSK to Build New Global Research Center in Cambridge","url":"https://stock-news.laohu8.com/highlight/detail?id=2654007170","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654007170?lang=en_us&edition=fundamental","pubTime":"2026-07-28 21:16","pubTimestamp":1785244607,"startTime":"0","endTime":"0","summary":"GSK  said Tuesday it plans to establish a new global research and development facility within Cambridge Biomedical Campus in the UK and spend 400 million British pounds  over three years to construct the center and upgrade existing laboratories in Ware.The company said it will move its R&D operations in the UK to the new facility, which is expected to house over 1,000 researchers, and exit its current site in Stevenage through a gradual employee relocation ending by 2029.Shares of the company were up 2.1% in Tuesday premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4532","BK4007","GSK","BGSX","LU1829250122.USD","BK4585","BK4588","GSK.UK","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654007174","title":"Sector Update: Healthcare Stocks Flat to Higher Pre-Bell Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2654007174","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654007174?lang=en_us&edition=fundamental","pubTime":"2026-07-28 21:15","pubTimestamp":1785244555,"startTime":"0","endTime":"0","summary":"Healthcare stocks were flat to higher pre-bell Tuesday, with the iShares Biotechnology ETF  inactive and the State Street Health Care Select Sector SPDR ETF  up 1.2%.GSK  shares were up more than 2% after the company posted higher Q2 core earnings and sales.IQVIA  stock was up more than 11% after the company reported higher Q2 adjusted earnings and revenue, and raised its 2026 outlook.Centene  shares were down more than 5% even after the company reported that it swung to Q2 adjusted earnings as revenue increased during the period. Centene also lifted its 2026 guidance.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2362540622.SGD","LU0130102774.USD","CNCG","LU0528227936.USD","VGFPF","LU0477156953.USD","FEBU","LABU","BK4585","GSK.UK","LU0130518102.USD","XLV","HEAL","JOYT","BK4530","BK4581","IBB","XBI","LU1791710582.SGD","DECU","IQV","VOTE","LU0128526141.USD","LU1261432733.SGD","GSK","LU2065169927.USD","CNC","LU1201861165.SGD","RGLO","LU0648001328.SGD","GXDW","LU1201861249.SGD","LU1989771016.USD","LU2362541273.HKD","BK4154","LU0029874061.USD","HCSG","LU1791710400.SGD","LU2357627491.SGD","LU0130103400.USD","PMDE","LU2065171311.SGD","LU1829250122.USD","GSKH","LU0130517989.USD","BK4137","BK4588","LU0980610538.SGD","EKG","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654002374","title":"GSK's R&D Plan Looks Smart","url":"https://stock-news.laohu8.com/highlight/detail?id=2654002374","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654002374?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:42","pubTimestamp":1785242520,"startTime":"0","endTime":"0","summary":"1242 GMT - GSK's plan to open a new research-and-development center in Cambridge, England, looks like a smart move that bodes well for its future prospects, Bernstein analysts say in a research note. \"We view this as a sound investment as this site already houses a major [AstraZeneca] R&D hub and two world leading academic hospitals,\" the analysts say. \"We think this should increase GSK's R&D productivity long term due to greater collaborations with academia.\" The U.K. drugmaker also plans more than 20 late-stage clinical trials to start this year, and is launching a three-year program to cut costs and fund investment in its late-stage portfolio, Bernstein says. Shares rise 1.4%.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK.UK","BK4588","BK4532","BK4585","BK4007","LU1829250122.USD","GSKH","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654041060","title":"GSK's Savings Plan Can Offset Profitability Hit from HIV Patent Expiration","url":"https://stock-news.laohu8.com/highlight/detail?id=2654041060","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654041060?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:19","pubTimestamp":1785241140,"startTime":"0","endTime":"0","summary":"1219 GMT - GSK's new cost-cutting plan means it is now possible for the U.K. drugmaker to offset the profitability hit from an HIV drug going off patent later this decade, Intron Health's Naresh Chouhan and Dominic Rose say in a note. The company aims to cut annual costs by 1.9 billion pounds by 2029, leading to a stable or improving operating margin coinciding with the patent-expiration period for HIV drug dolutegravir between 2028 and 2030. This suggests consensus estimates could go up by 50 to 100 basis points, Intron says. Still, the company's target of generating more than 40 billion pounds in 2031 sales looks out of reach, the analysts say. Shares trade 0.3% higher.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK.UK","BK4007","LU1829250122.USD","GSK","BK4585","BK4532","GSKH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654500183","title":"GSK sees 70p per share dividend for FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2654500183","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654500183?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:41","pubTimestamp":1785238881,"startTime":"0","endTime":"0","summary":"07:36 EDT GSK (GSK) sees 70p per share dividend for FY26 Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsk-sees-70p-per-share-dividend-for-fy26-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsk-sees-70p-per-share-dividend-for-fy26-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1829250122.USD","GSK.UK","BK4588","BK4007","BK4585","GSK","GSKH","BK4532","VIG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654000188","title":"GSK initiates ‘Accelerate Growth’ program","url":"https://stock-news.laohu8.com/highlight/detail?id=2654000188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654000188?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:40","pubTimestamp":1785238820,"startTime":"0","endTime":"0","summary":"The company said, “Following review, the company has identified asset accelerations – across 18 indications – for 7 late-stage products in Oncology...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsk-initiates-accelerate-growth-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsk-initiates-accelerate-growth-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK.UK","GSKH","BK4007","BK4585","BK4588","AAQC","LU1829250122.USD","GSK","BK4532"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}